Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

This study tests BGT007H, an experimental CAR-T cell therapy (where a patient's own immune cells are engineered to attack cancer), in patients with pancreatic cancer that has returned or stopped responding to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced pancreatic cancer that has progressed after at least two prior treatments - Your expected survival is at least 3 months - Your overall health and organ function are adequate (ECOG 0 or 1) **You may NOT be eligible if...** - You have never received prior chemotherapy for pancreatic cancer - You have severe organ impairment - You have active infections or autoimmune conditions - Your cancer has invaded major blood vessels in ways that make treatment unsafe Talk to your doctor to see if this trial is right for you.